Abstract

Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria, regardless of age, lymph node status, tumor size, or estrogen receptor status, are candidates for chemotherapy.

Keywords

TamoxifenMedicineBreast cancerOncologyLumpectomyChemotherapyInternal medicineAntiestrogenCyclophosphamideEstrogen receptorAxillary lymph nodesAdjuvant therapyCancerMastectomy

Affiliated Institutions

Related Publications

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.

Bernard Fisher , Carol Redmond , S Legault-Poisson +7 more

The National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted a randomized clinical trial to determine whether tamoxifen (TAM) plus chemotherapy is more effective th...

1990 Journal of Clinical Oncology 294 citations

Publication Info

Year
1997
Type
article
Volume
89
Issue
22
Pages
1673-1682
Citations
521
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

521
OpenAlex

Cite This

Bernard Fisher, James J. Dignam, Birol Emir et al. (1997). Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer. JNCI Journal of the National Cancer Institute , 89 (22) , 1673-1682. https://doi.org/10.1093/jnci/89.22.1673

Identifiers

DOI
10.1093/jnci/89.22.1673